BEMA Fentanyl

Phase 3Small molecule

BBioDelivery Sciences International

BEMA Fentanyl is one of 70 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Chronic PainActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Low Back Pain

#DrugCompanyPhaseTrials

Arcoxia

Novartis

Phase 3

1 2

Sympazan

Lundbeck

Phase 3

1 3

Suboxone

IIndivior Inc.

Phase 3

4 4

Voltaren

CCerimon Pharmaceuticals

Phase 3

1 5

Tanezumab

Pfizer

Phase 3

4 6

Anjeso

Boehringer Ingelheim

Phase 3

1 7

Botox

RRevance Therapeutics, Inc.

Phase 3

1 8

Detrol La

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Hydrocodone/acetaminophen

AbbVie

Phase 3

2 10

Remicade

OOrganon and Co

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Buprenorphine2 trials

The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects

Withdrawn·BBioDelivery Sciences International·Phase 3·NCT02516436

An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects

Completed·BBioDelivery Sciences International·Phase 2·NCT01666119·249 enrolled

Chronic pain1 trial

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain

Completed·BBioDelivery Sciences International·Phase 3·NCT01298765·302 enrolled

Low back pain1 trial

Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Low Back Pain

Withdrawn·BBioDelivery Sciences International·Phase 3·NCT01431742

Fentanyl1 trial

Long-term Extension Study of BEMA™ Fentanyl

Completed·BBioDelivery Sciences International·Phase 3·NCT00696137·5 enrolled

Breakthrough Pain1 trial

Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

Completed·BBioDelivery Sciences International·Phase 3·NCT00293020·244 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for BEMA Fentanyl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BEMA Fentanyl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BEMA Fentanyl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioDelivery Sciences International company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBioDelivery Sciences International

BEMA Fentanyl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Buprenorphine2 trials

Chronic pain1 trial

Low back pain1 trial

Fentanyl1 trial

Breakthrough Pain1 trial

References

Drug Info

Quick Facts

Related News